Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2020

01-10-2020 | Meningococcus | Original Article

The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta

Authors: David Pace, Charmaine Gauci, Christopher Barbara

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2020

Login to get access

Abstract

Invasive meningococcal disease (IMD) is a vaccine-preventable devastating infection that mainly affects infants, children and adolescents. We describe the population epidemiology of IMD in Malta in order to assess the potential utility of a meningococcal vaccination programme. All cases of microbiologically confirmed IMD in the Maltese population from 2000 to 2017 were analysed to quantify the overall and capsular-specific disease burden. Mean overall crude and age-specific meningococcal incidence rates were calculated to identify the target age groups that would benefit from vaccination. Over the 18-year study period, 111 out of the 245 eligible notified cases were confirmed microbiologically of which 70.3% had septicaemia, 21.6% had meningitis, and 6.3% had both. The mean overall crude incidence rate was 1.49/100,000 population with an overall case fatality rate of 12.6%. Meningococcal capsular groups (Men) B followed by C were the most prevalent with W and Y appearing over the last 6 years. Infants had the highest meningococcal incidence rate of 18.9/100,000 followed by 6.1/100,000 in 1–5 year olds and 3.6/100,000 in 11–15 year old adolescents. The introduction of MenACWY and MenB vaccines on the national immunization schedule in Malta would be expected to reduce the disease burden of meningococcal disease in children and adolescents in Malta.
Literature
1.
ECDC: European Centre for Disease Prevention and Control. Surveillance Report. Invasive meningococcal disease. Annual Epidemiological Report for 2017. Stockholm 2019. Available from https://​ecdc.​europa.​eu/​sites/​portal/​ files/documents/AER_for_2017-invasive-meningococcal-disease.pdf. Accessed 20th April, 2020
2.
3.
Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H (2019) Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 37(21):2768–2782PubMed
4.
Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA (2015) Investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT). Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis 60(8):e27–e35PubMed
5.
Davis KL, Misurski D, Miller J, Karve S (2011) Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin 7(4):458–465PubMed
6.
Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D (2014) The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis 33(7):777–779
7.
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11(9):774–783PubMed
8.
Mohammed I, Iliyasu G, Habib AG (2017) Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health 111:1–6PubMedPubMedCentral
9.
Kretz CB, Retchless AC, Sidikou F, Issaka B, Ousmane S, Schwartz S, Tate AH, Pana A, Njanpop-Lafourcade BM, Nzeyimana I et al (2016) Whole-genome characterization of epidemic Neisseria meningitidis serogroup C and resurgence of serogroup W, Niger, 2015. Emerg Infect Dis 22:1762–1768PubMedPubMedCentral
10.
Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A et al (2011) Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 6:e19513PubMedPubMedCentral
11.
Yezli S (2018) The threat of meningococcal disease during the Hajj and Umrah mass gatherings: a comprehensive review. Travel Med Infect Dis 24:51–58PubMed
12.
Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431):365–367PubMed
13.
de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25(1):79–80PubMed
14.
Larrauri A, Cano R, García M, de Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23(32):4097–4100PubMed
15.
do Macedo LE, Ferreira VM, Feitosa CA, Nunes AMPB, Campos LC, Sáfadi MAP (2018) Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: lessons learned from Bahia. Brazil Hum Vaccin Immunother 14(5):1131–1137
16.
Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Preziosi MP, Stuart JM (2017) Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis 17:867–872PubMed
17.
Villena R, Valenzuela MT, Bastías M, Santolaya ME (2019) Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 37(46):6915–6921PubMed
18.
Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P (2020) Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med 382(4):318–327PubMed
19.
McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, Jenkins LT, Wang X (2017) Acosta ; Oregon Meningococcal Carriage Team. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a universityserogroup B meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis 216(9):1130–1140PubMedPubMedCentral
20.
21.
National Statistics Office, Malta. 2014. Census of Population and Housing, 2011. Available from www.​nso.​gov.​mt. Accessed 7th October, 2019
22.
The European Commission. Official Journal of the European Union. Decisions. 2012/506/EU; L262:1–56
23.
Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the meningococcal reference unit. J Med MicrobiolJ 55(Pt 7):887–896
24.
The Commission of the European Communities. Official Journal of the European Communities. 2002/253/EC;L86:44–62
25.
The Commission of the European Communities. Commission Decision. 28/IV/2008;1–79
26.
EU-IBIS Network: European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2003/2004. Health Protection Agency, London 2006. Available from www.​euibis.​org. Accessed 10th June, 2016
27.
EU-IBIS Network: European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London 2006. Available from www.​euibis.​org. Accessed 20th April, 2020
28.
ECDC: European Centre for Disease Prevention and Control. Surveillance network for invasive Neisseria meningitidis in Europe – 1999 & 2000. ECDC 2007. Available from http://​www.​ecdc.​europa.​eu. Accessed 20th April, 2020
29.
European Centre for Disease Prevention and Control. Invasive meningococcal disease. Annual Epidemiological Report on communicable diseases in Europe (2007) Reporting on 2005 surveillance data. ECDC, Stockholm
30.
European Centre for Disease Prevention and Control. Annual Epidemiological Report. Reporting on 2007–2011 surveillance data. Stockholm: ECDC; 2009–2013
31.
European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – vaccine-preventable diseases – invasive bacterial diseases. Stockholm: ECDC; 2015
32.
European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological reports for 2015–2017. Stockholm: ECDC; 2016–2019
33.
34.
Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L (2019) Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother 15(2):459–469PubMed
35.
(2007) Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR 56:794–795
36.
Page AL, Coldiron ME, Gamougam K, Acyl MA, Tamadji M, Lastrucci C, Hurtado N, Tehoua FC, Fermon F, Caugant DA, Porten K (2017) Four years of case-based surveillance of meningitis following the introduction of MenAfriVac in Moissala, Chad: lessons learned. Trop Med Int Health 22(12):1561–1568PubMed
37.
Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME (2020) Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med 382(4):309–317PubMed
38.
Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180(6):1894–1901PubMed
39.
Galdies C (2011) The Climate of Malta: statistics, trends and analysis 1951-2010. National Statistics Office, Malta
40.
Kinlin LM, Spain CV, Ng V, Johnson CC, White AN, Fisman DN (2009) Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales. Am J Epidemiol 169(5):588–595PubMedPubMedCentral
41.
Malta Tourism Authority. Tourism in Malta. Editions 2015 to 2017
42.
Cartwright KA, Stuart JM, Jones DM, Noah ND (1987) The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99(3):591–601PubMedPubMedCentral
43.
MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter DN, Maiden MC, Stuart JM, United Kingdom meningococcal carriage group (2006) Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 12(6):950–957PubMedPubMedCentral
44.
Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, Vanner C, Chang HY, Vuong JT, Martin S, MacNeil JR, Wang X, Meyer SA (2018) Meningococcal carriage among a university student population - United States, 2015. Vaccine. 36(1):29–35PubMed
45.
van Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VMD, Anderson AS, Eiden J, Hao L, Jansen KU, Jones H, Kitchin N, Pedneault L, Sanders EAM, van der Ende A (2017) Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. Clin Microbiol Infect 23(8):573.e1–573.e7
46.
Díaz J, Cárcamo M, Seoane M, Pidal P, Cavada G, Puentes R, Terrazas S, Araya P, Ibarz-Pavon AB, Manríquez M, Hormazábal JC, Ayala S, Valenzuela MT (2016) Prevalence of meningococcal carriage in children and adolescents aged 10-19 years in Chile in 2013. J Infect Public Health 9(4):506–515PubMed
47.
Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN (2016) Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 388(10061):2775–2782PubMed
48.
Trotter C, Borrow R, Andrews N, Miller E (2003) Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 21(11–12):1094–1098PubMed
49.
Jansen AG, Sanders EA, Van Der Ende A, Van Loon AM, Hoes AW, Hak E (2008) Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? Epidemiol Infect 136(11):1448–1454PubMedPubMedCentral
50.
Bröker M, Emonet S, Fazio C, Jacobsson S, Koliou M, Kuusi M, Pace D, Paragi M, Pysik A, Simões MJ, Skoczynska A, Stefanelli P, Toropainen M, Taha MK, Tzanakaki G (2015) Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother 11(9):2281–2286PubMedPubMedCentral
51.
Glode MP, Robbins JB, Liu TY, Gotschlich EC, Orskov I, Orskov F (1977) Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 135(1):94–104PubMed
52.
Troncoso G, Sánchez S, Moreda M, Criado MT, Ferreirós CM (2000) Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol Med Microbiol 27(2):103–109PubMed
53.
Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194PubMed
54.
Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50(2):184–191PubMed
55.
Waśko I, Hryniewicz W, Skoczyńska A (2015) Significance of meningococcal hyperinvasive clonal complexes and their influence on vaccines development. Pol J Microbiol 64(4):313–321PubMed
56.
Jelfs J, Munro R, Ashto FE, Caugant DA (2000) Genetic characterization of a new variant within the ET-37 complex of Neisseria meningitidis associated with outbreaks in various parts of the world. Epidemiol Infect 125(2):285–298PubMedPubMedCentral
57.
Jandova Z, Musilek M, Vackova Z, Kozakova J, Krizova P (2016) Serogroup and clonal characterization of Czech invasive Neisseria meningitidis strains isolated from 1971 to 2015. PLoS One 11(12):e0167762PubMedPubMedCentral
58.
Jounio U, Saukkoriipi A, Bratcher HB, Bloigu A, Juvonen R, Silvennoinen-Kassinen S, Peitso A, Harju T, Vainio O, Kuusi M, Maiden MC, Leinonen M, Käyhty H, Toropainen M (2012) Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol 50(2):264–273PubMedPubMedCentral
59.
GlaxoSmithKline Vaccines (2019) Summary of product characteristics: Bexsero meningococcal group B vaccine for injection in pre-filled syringe. Available from www.​medicines.​org.​uk. Accessed 17th October, 2019
60.
61.
Arnold R, Galloway Y, McNicholas A, O'Hallahan J (2011) Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 29(40):7100–7106PubMed
62.
Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J (2009) Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 38(2):413–418PubMed
63.
Martinón-Torres F, Nolan T, Toneatto D, Banzhoff A (2019) Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother 9:1–12
64.
Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K, Miller E (2002) Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 186(9):1353–1357PubMed
65.
Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, Birks J, Voysey M, White C, Finn A, Macloed E, Faust SN, Kent AL, Heath PT, Borrow R, Snape MD, Pollard AJ (2015;350:h1554. Erratum in: BMJ. 2016 May 06) Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ 353:i2605
66.
Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ (2012) Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 30(18):2831–2838PubMed
67.
Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM (2016) Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother 12(1):132–139PubMed
68.
Wormsbecker AE, Wong K, Jamieson FB, Crowcroft NS, Deeks SL (2015) Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: vaccine program impact assessment. Vaccine. 33(42):5678–5683PubMed
69.
Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY (2012) Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infect Dis 12:35PubMedPubMedCentral
70.
Campbell H, Borrow R, Salisbury D, Miller E (2009) Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 27(Suppl 2):B20–B29PubMed
Metadata
Title
The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta
Authors
David Pace
Charmaine Gauci
Christopher Barbara
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03914-8

Other articles of this Issue 10/2020

European Journal of Clinical Microbiology & Infectious Diseases 10/2020 Go to the issue

Brief Report

The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?

Review

Mechanism of Candida pathogenesis: revisiting the vital drivers

Review

Virulence of Helicobacter pylori outer membrane proteins: an updated review

Correction

Correction to: Evaluation of two rapid molecular test systems to establish an algorithm for fast identification of bacterial pathogens from positive blood cultures

Original Article

Evaluation of ultra-rapid susceptibility testing of ceftolozane-tazobactam by a flow cytometry assay directly from positive blood cultures

Original Article

Clinical characteristics and outcomes of Staphylococcus aureus bacteremia from a biliary source
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits